Osimertinib Real World Toxicity Substantially Less than 1st Gen TKIs

Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center discusses Osimertinib and the real world toxicity issues including that it's substantially less than 1st generationg TKIs from the 22nd... Author: thoraciconcology Added: 12/29/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts